[
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975666",
    "id": "02975666",
    "pages": 2,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwwc2rtwrgv.pdf",
    "summary": "<ul>\n<li><strong>R&amp;D Pipeline</strong>: Targets addressable markets worth over <strong>US$8 billion</strong>, with 8 patented products and 24 off-patent injectables in development.  </li>\n<li><strong>FY26 Guidance</strong>: Operating profit expected at <strong>$20.0\u201324.0 million</strong>.  </li>\n<li><strong>FY27 Revenue Target</strong>: <strong>$300 million</strong>, supported by market expansion investments.  </li>\n<li><strong>Key Commercialization Programs</strong>: Maxigesic\u00ae, Crystaderm\u00ae, Micolette\u00ae, Kiwisoothe\u00ae, and capsaicin cream for osteoarthritis/neuropathic pain.  </li>\n</ul>\n<p><em>No capital markets actions (e.g., raising, halt) or material liquidity/capital structure updates identified.</em></p>",
    "usage": {
      "prompt_tokens": 1072,
      "completion_tokens": 137,
      "total_tokens": 1209,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:32:53.487542"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
    "id": "02975667",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
    "summary": "<ul>\n<li><strong>Revenue milestone</strong>: Annual sales reached <strong>AUD 208 million</strong> (first time exceeding AUD 200 million).  </li>\n<li><strong>Geographic expansion</strong>: Launched Maxigesic IV/tablet (as Combogesic) in <strong>North America</strong> (US and Canada), with a combined addressable market of <strong>over USD 8 billion</strong>.  </li>\n<li><strong>R&amp;D pipeline</strong>: Eight patented products in development, including migraine treatments and 24 off-patent injectables; five programs nearing commercialization (e.g., Maxigesic variants, Crystaderm).  </li>\n<li><strong>Financials</strong>: Net debt reduced to <strong>AUD 14.5 million</strong> (from AUD 16.2 million); dividend increased to <strong>1.8 cents/share</strong> (from 1.6 cents).  </li>\n<li><strong>FY27 target</strong>: Revenue goal of <strong>AUD 300 million</strong>, supported by market expansion.  </li>\n</ul>\n<p><em>Omitted: Governance updates, board changes, and non-material operational commentary.</em></p>",
    "usage": {
      "prompt_tokens": 1984,
      "completion_tokens": 200,
      "total_tokens": 2184,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:33:28.952185"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
    "id": "02975668",
    "pages": 30,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
    "summary": "<h3>Summary of ASX Announcement: <strong>AFT Pharmaceuticals 2025 Annual Shareholders' Meeting Presentation</strong></h3>\n<h4><strong>Material Information for Capital Markets/Trading Decisions:</strong></h4>\n<ul>\n<li><strong>FY25 Financial Highlights</strong>  </li>\n<li><strong>Revenue</strong>: NZD $208.0M (6% YoY growth; 5-year CAGR: 14%).  </li>\n<li><strong>Operating Profit</strong>: NZD $17.6M (vs. NZD $24.2M in FY24), impacted by lower licensing income (NZD $0.7M vs. NZD $8.5M in FY24) and strategic investments.  </li>\n<li><strong>Dividend</strong>: 1.8 NZ cents per share (up from 1.6 NZ cps in FY24).  </li>\n<li><strong>Net Debt</strong>: NZD $14.5M (down from NZD $16.2M in FY24); debt-to-equity ratio declining.  </li>\n<li>\n<p><strong>Cash Flow</strong>: R&amp;D spend increased to NZD $15.0M (FY24: NZD $12.4M).  </p>\n</li>\n<li>\n<p><strong>Operational Highlights</strong>  </p>\n</li>\n<li><strong>ANZ Growth</strong>: Australia sales up 17% (NZD $53.8M); New Zealand sales NZD $127.1M.  </li>\n<li><strong>International</strong>: Sales in ~80 countries; product/royalty income NZD $15.4M (down from NZD $19.3M due to destocking).  </li>\n<li><strong>Product Pipeline</strong>: 8 patented products in development; 24+ off-patent injectables progressing.  </li>\n<li>\n<p><strong>Expansion</strong>: Launches in UK, EU, USA, Canada, South Africa, and Asia (Hong Kong/Singapore).  </p>\n</li>\n<li>\n<p><strong>Outlook</strong>  </p>\n</li>\n<li><strong>FY26 Guidance</strong>: Operating profit expected between NZD $20M\u201324M.  </li>\n<li><strong>FY27 Target</strong>: Revenue goal of NZD $300M.  </li>\n</ul>\n<h4><strong>Other Material Points</strong></h4>\n<ul>\n<li><strong>Governance</strong>: Allison Yorston appointed as Independent Director; ESG targets met.  </li>\n<li><strong>R&amp;D</strong>: Focus on commercialization of Maxigesic variants (IV, pediatric, oral) and novel therapies (e.g., Pascomer for Prader-Willi syndrome, Iron IV).  </li>\n</ul>\n<h4><strong>Omitted</strong>: Board nominations (Resolution 2\u20133), auditor remuneration, historical/organizational details.</h4>\n<p><strong>Format Note</strong>: Structured for brevity; excluded operational minutiae and non-material resolutions.</p>",
    "usage": {
      "prompt_tokens": 5861,
      "completion_tokens": 511,
      "total_tokens": 6372,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:33:22.491195"
  }
]